Objective:

The article examines the objective, findings, and clinical context described in Global Approaches and Expert Recommendations for Starting Biologics in Atopic Dermatitis: Findings from the AMAZE Project.

Approach:

• Design: Mixed-methods project combining a narrative literature review, an online dermatologist survey, regional expert meetings, and global steering committee oversight.
• Survey and consensus: A double-blinded survey was completed by 150 dermatologists worldwide in October and November 2024. Experts reviewed aggregated results and formulated recommendations in June 2025.

Key Findings:

• Survey responses showed substantial variation in biologic initiation and management, particularly in transitions from conventional systemic therapies, follow-up scheduling, and expected treatment duration.
• Transition strategies included overlapping therapies, direct switches, and washout periods; approaches varied with prior treatment, local practice, and healthcare-system requirements.
• Expert recommendations included setting patient-centered treatment goals, tailoring transition strategies, assessing response at approximately 12–16 weeks, and continuing background topical therapy to manage flares and support long-term disease control.

Interpretation:

The project describes variation in routine biologic practice and presents expert-informed recommendations for initiation and follow-up in moderate-to-severe AD.

Limitations:

• The provided article context does not report detailed survey methods, participant characteristics, regional response distributions, or the full recommendation set.
• The recommendations were developed through expert consensus informed by survey findings and available evidence.

Conclusion:

AMAZE identified differences in how dermatologists initiate and manage biologics and developed practical recommendations addressing treatment goals, therapy transitions, response assessment, and topical treatment.

Sources:

• Digital features and plain-language summary